- You are here:
- Home »
- Blog »
- breast cancer »
- Breast Cancer and AHCC
Breast Cancer and AHCC
Breast cancer and AHCC (Active Hexose Correlated Compound), a mushroom-derived extract (primarily from cultured Lentinula edodes mycelia) rich in α-glucans, is commonly marketed as an immune-support supplement. It has been studied as a complementary therapy for cancer patients, including those with breast cancer.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. When I discovered that my risk of an MM diagnosis was increased by HPV, I decided to take AHCC in an effort to clear the HPV in my body.
When I was blogging about evidence-based therapies to support cancer patients, I wondered about AHCC and its effect on the side effects of cancer patients undergoing chemotherapy and radiation.
Below is an evidence-based overview of the potential pros and cons of AHCC supplementation specifically relevant to breast cancer patients, with active research links.
Feel free to scroll down the page and post a question or comment. I will reply to you ASAP.
Thanks,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Use of AHCC to Reduce Chemotherapy Side-Effects.
AHCC and Breast Cancer: Pros and Cons
Potential Benefits (Pros)
1. Immune system support
AHCC appears to stimulate components of both innate and adaptive immunity, including natural killer (NK) cells and T-cells, which are involved in tumor surveillance.
- AHCC increases NK and T-cell activity in laboratory and animal studies.
- These immune cells are important for identifying and destroying cancer cells.
Research:
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11030784/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6942843/
Clinical relevance:
For breast cancer survivors with immune suppression (for example, after chemotherapy), immune-modulating supplements may theoretically help immune recovery.
2. May reduce chemotherapy side effects
A clinical study involving breast cancer patients receiving chemotherapy found that AHCC supplementation was associated with fewer neutropenia events (low white blood cells).
- Patients taking AHCC had fewer adverse neutrophil events and less need for G-CSF during taxane chemotherapy.
Research:
Clinical relevance:
Neutropenia is a common chemotherapy toxicity that increases infection risk.
3. Potential anti-tumor activity (preclinical evidence)
Laboratory and animal studies suggest AHCC may have direct or indirect anti-cancer effects, including tumor growth inhibition.
- AHCC showed cytotoxic effects in breast cancer tumor models.
Research:
However, this evidence is preclinical and not proof of effectiveness in humans.
4. Generally well tolerated
Clinical trials and reviews report good safety and tolerability in humans, with few serious adverse events.
- A Phase I safety study found AHCC safe at multiple doses in humans.
- Reviews of cancer patients suggest it may help reduce treatment-related side effects.
Research:
- https://pubmed.ncbi.nlm.nih.gov/18202543/
- https://www.cancertherapyadvisor.com/factsheets/ahcc-and-cancer/
Potential Risks or Limitations (Cons)
1. Possible interaction with hormone-related pathways
One breast cancer study suggested AHCC may increase aromatase activity, the enzyme that produces estrogen.
- Increased aromatase could theoretically raise estrogen levels.
Research:
Why this matters:
Many breast cancers are estrogen-receptor positive, and increased estrogen could potentially promote tumor growth in susceptible patients.
2. Possible interaction with endocrine therapies
In the same research, AHCC showed mixed effects when combined with the aromatase inhibitor letrozoledepending on genetic factors (COMT genotype).
Potential concerns:
- May alter estrogen metabolism
- Possible impact on aromatase inhibitor efficacy in some cases
Evidence is limited and not definitive.
3. Limited human breast cancer trials
Although AHCC is widely studied in complementary oncology, high-quality clinical trials specifically in breast cancer are scarce.
Most evidence comes from:
- animal studies
- laboratory models
- small clinical studies
- studies in other cancers
Experts generally conclude that larger randomized trials are needed.
4. Supplement regulation and variability
AHCC is sold as a dietary supplement, meaning:
- products are not FDA-approved cancer therapies
- potency and quality can vary between manufacturers
- Patients should only use reputable brands and consult oncologists.
Practical Considerations for Breast Cancer Patients
Patients sometimes consider AHCC during:
- chemotherapy
- immunotherapy
- survivorship immune recovery
However, clinicians typically recommend caution if the patient is taking:
- aromatase inhibitors (letrozole, anastrozole, exemestane)
- tamoxifen
- other endocrine therapies
because of possible metabolic interactions.
Typical Dosage Used in Studies
Most clinical trials use:
1–3 grams/day orally
Example:
- 3 g daily in immune-modulation trials.
Research:
https://www.frontiersin.org/articles/10.3389/fonc.2022.881902/full
Bottom Line
Potential advantages
- Immune system support (NK cells, T cells)
- May reduce chemotherapy side effects
- Possible anti-tumor activity (preclinical)
- Generally well tolerated
Potential concerns
- Possible increase in aromatase activity (estrogen production)
- Possible interaction with endocrine therapy
- Limited breast-cancer–specific clinical trials
- Supplement quality variability
✅ Evidence summary:
AHCC is a promising immune-support supplement, but it should be viewed as a complementary therapy rather than a cancer treatment, and breast cancer patients—especially those with hormone-receptor-positive disease—should discuss it with their oncologist before use.
To Learn More About Complementary Therapies
Breast cancer and AHCC Breast cancer and AHCC Breast cancer and AHCC